QCG
ALXN

Quadrant Capital Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Quadrant Capital Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,279
Closed -$235K – 2741
2021
Q2 		$235K Sell
1,279
-36
-3% -$6.18K 0.03% 342
2021
Q1 		$201K Buy
1,315
+627
+91% +$97K 0.03% 354
2020
Q4 		$107K Sell
688
-62
-8% -$7.97K 0.02% 478
2020
Q3 		$86K Buy
750
+282
+60% +$30.4K 0.02% 477
2020
Q2 		$53K Buy
468
+129
+38% +$13.7K 0.01% 698
2020
Q1 		$33K Sell
339
-474
-58% -$46.5K 0.01% 1078
2019
Q4 		$82K Buy
813
+583
+253% +$62.4K 0.01% 1089
2019
Q3 		$18K Sell
230
-29
-11% -$3.27K ﹤0.01% 1626
2019
Q2 		$28K Sell
259
-631
-71% -$81.3K ﹤0.01% 1500
2019
Q1 		$115K Buy
890
+725
+439% +$90.2K 0.02% 736
2018
Q4 		$11K Sell
165
-52
-24% -$6.15K ﹤0.01% 1371
2018
Q3 		$26K Sell
217
-11
-5% -$1.38K 0.01% 880
2018
Q2 		$22K Buy
228
+7
+3% +$818 0.01% 944
2018
Q1 		$19K Buy
221
+76
+52% +$9.08K 0.01% 982
2017
Q4 		$14K Sell
145
-15
-9% -$1.83K 0.01% 1061
2017
Q3 		$18K Buy
160
+51
+47% +$6.93K 0.01% 955
2017
Q2 		$10K Sell
109
-163
-60% -$19K ﹤0.01% 1122
2017
Q1 		$28K Buy
272
+75
+38% +$9.67K 0.01% 740
2016
Q4 		$20K Buy
197
+64
+48% +$7.83K 0.01% 763
2016
Q3 		$13K Buy
133
+73
+122% +$9.4K 0.01% 959
2016
Q2 		$3K Sell
60
-213
-78% -$30.2K ﹤0.01% 1384
2016
Q1 		$33K Buy
273
+90
+49% +$13.2K 0.02% 517
2015
Q4 		$30K Sell
183
-551
-75% -$96.3K 0.02% 476
2015
Q3 		$113K Buy
734
+2
+0.3% +$365 0.08% 219
2015
Q2 		$130K Buy
+732
New +$126K 0.08% 202

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Quadrant Capital Group's ALXN Position: Q3 2021 in Review

Quadrant Capital Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,279 shares — an estimated $235K sold.

Quadrant Capital Group first reported a position in ALXN in Q2 2015 and held it in 25 quarters. The position peaked at $235K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Quadrant Capital Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 1,279 Alexion Pharmaceuticals shares in Q3 2021, an estimated $235K.
  • Quadrant Capital Group first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 25 quarters.
  • Quadrant Capital Group's Alexion Pharmaceuticals position peaked at $235K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.